Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
226 Leser
Artikel bewerten:
(1)

Solar Biotech Acquires Noblegen

Solar Biotech Canada will transform consumer goods to ensure a sustainable future

NORTON, Va. and PETERBOROUGH, ON, July 25, 2023 /PRNewswire/ -- Solar Biotech Inc., a Norton, Virginia-based provider of complete sustainable and scalable biomanufacturing solutions, continues to build out its vertically integrated organization by acquiring Noblegen, an advanced digital biology company based in Peterborough, Ontario, Canada.

Noblegen will now operate under the name Solar Biotech Canada, continuing as the organization's food-grade-certified (SQF9) biomanufacturing and research & development hub in Canada. The new company will leverage both partners' strengths in microbiology and biomanufacturing to offer revolutionary biotech and synthetic biology ("SynBio") solutions for a wide range of applications.

"This is a significant step forward for Solar Biotech and its industrial partners since it immediately brings online much-needed capacity and expertise in the biomanufacturing industry. We are bringing together two innovative companies with complementary intellectual property portfolios and sector experience that will help us make a lasting impact on the world.", said Alex Berlin, CEO of Solar Biotech, and the newly appointed Chairman of Solar Biotech Canada.

Solar Biotech Canada's extensive upstream and downstream capabilities, resulting from a US$40M in infrastructure and technology development investment over the past nine years, will be available to existing and new customers and partners.

The company aims to bolster the bioeconomy by supporting start-up innovators' ideation, technology development, and scale-up at the development and production phases. It will focus on supporting the development of processes and products from a wide diversity of microorganisms like bacteria, fungi, yeasts, and microalgae.

"At the core of Solar Biotech Canada is the reality that real solutions to real problems can only be achieved through collaboration and joint efforts.", said Mark Iliopoulos, VP Business & Commercial Operations Canada. "Through Solar Biotech Canada, we will empower innovation and emerging technologies to market sooner. We encourage companies seeking support in scaling, optimizing, and commercializing their technology to connect with us."

Solar Biotech Canada plans to leverage government support to further develop its industrial site and highly qualified team in the historically industrial area, Peterborough, Ontario, located 90 minutes outside Toronto. The Peterborough-based biomanufacturing facility, which can be operated with nearly 100%-emissions-free energy, comprises a fully equipped biomanufacturing hub with a total nominal capacity of over 160,000 liters of upstream precision fermentation and extensive downstream processing equipment, including spray- and freeze-drying, and innovation and analytical labs based at Trent University.

About Solar Biotech

Solar Biotech, Inc. is a leading SynBio products and advanced bioprocessing technology development company with a mission to transform the way consumer products are manufactured via advanced bioprocessing technologies, including precision fermentation. The research and development and biomanufacturing facility in Norton, Virginia, has facilitated over the past years the successful introduction of several major products to the SynBio food and beverage and other market segments. Recognizing rising consumer trends for sustainable, traceable, and healthier consumer goods, Solar Biotech is committed to environmentally sound operations to deliver the highest quality SynBio products available worldwide. Solar Biotech is working on the next generation of sustainable bioprocessing technologies to revolutionize the SynBio industry. To learn more about Solar Biotech, visit www.solarbiotech.com.

For media inquiries, please contact: Mark Iliopoulos, VP Business & Commercial Operations Canada, mark.iliopoulos@solarbiotech.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/solar-biotech-acquires-noblegen-301884994.html

© 2023 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.